51 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm
recruitment is underway in the U.S.-based Phase 1/2 clinical trial of CHS-006, a TIGIT-targeted antibody in combination with toripalimab in patients
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 May 21
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:24pm
to facilitate the potential BLA submission. Recruitment into the study has been slower than expected as a result of the COVID-19 pandemic, and Coherus
10-K
wuahbg6 orrbk2mqbu
23 Mar 15
Annual report
12:00am
DRS
5ppxsqexu1q qr6t0
4 Aug 14
Draft registration statement
12:00am